MultiplAI is becoming OmnigenicsAI to pioneer a new future in preventative health management through AI-driven genomic health data.

View press release

We're making cardiovascular screening possible for anyone on earth

MultiplAI Health is developing ground-breaking RNA-based, AI-driven screening technology in the form of a simple blood test to transform how cardiovascular diseases are diagnosed.

The challenge we choose to face

Cardiovascular diseases are the leading cause of mortality globally, responsible for almost 18 million deaths per year.

Today, diagnostics are often inaccurate and time-consuming. General practitioners still rely on single biochemical markers such as cholesterol and blood pressure, which can fail to recognise the signs of increased risk of suffering a major cardiovascular event. In turn, late diagnosis and inadequate prognosis decrease the chances for successful intervention with primary cardiovascular preventive measures, ultimately creating financial and psychological strain for the patient, their families and their doctors.

We want to change this by making routine and frequent screening for cardiovascular diseases possible for anyone on earth.

Image of. RNA

Our solution

We offer a whole blood screening test using RNA Sequencing and Artificial Intelligence to detect complex diseases, including cardiovascular disorders and cancer.

Rather than searching for a single molecule that identifies a cardiovascular risk, our test identifies molecular variances in the blood that indicate an increased risk of a cardiovascular event.  Imagine measuring all blood RNA changes that a cardiac risk factor may induce at the same time: A powerful, deep and accurate superbiomarker.

This gives MultiplAI the power to:

  • Accuracy: our approach brings precision medicine to cardiovascular and other complex diseases as has been done with DNA for cancer
  • Simplified results: less confusing or ambiguous results when compared to existing cardiac screening methods
  • Timely intervention: allows more timely and successful intervention to prevent heart attack or stroke based on evidence not previously seen
  • Universal access: our use of a simple whole blood biopsy and the exponentially decreasing costs of sequencing makes CVD screening affordable and widely accessible to virtually anyone in the world
  • Improved treatment efficacy assessment: provides the ability to assess and adjust treatment regimens with more confidence

Timing is everything

MultiplAI brings together maturing artificial intelligence algorithms, cost-effective next-gen sequencing and remote medicine to detect cardiovascular and other complex diseases to better establish prognosis based on the biological substrate.

It’s time to imagine modern universal remote screening for cardiovascular diseases.

Introducing the


With advances in RNA sequencing, bioinformatic processing and deep learning, we now have the power to measure many biomarkers in the blood.

Our patented RNAseq data transformation process makes it possible to represent the incredible complexity of RNA in highly efficient formats ideal for algorithmic analysis.


Our team


Carlos Luzzani - Co-Founder and CSO

Dr. Charlie Luzzani

Co-Founder, CSO, CPO

Molecular biologist and biotech
specialist with experience
co-founding a bioprinting startup
(WeBio). Investigator at
peer-reviewed publications.

Dr. Santiago Miriuka, MD MSc PhD

Co-Founder, CEO. CTO

Medical Doctor with 20+ years in
clinical cardiology. Director of a basic and translational lab working on cutting-edge cellular and molecular biology. Data scientist and coder looking to innovate in medicine.

Mark Ramondt - Co-founder and  CFO

Mark Ramondt

Co-Founder, COO, CFO

Serial entrepreneur, angel investor
and advisor to startups with 25+
years of corporate finance and
open innovation experience.

Meg Samek-Smith

President, CRO

Global leader, with extensive experience co-founder and building early-stage science and technology companies worldwide covering diverse sectors from banking, consumer products, to security, and molecular biology lab business.


María Carolina Aliaga

People Manager

Romina Aramburu


Alejandro La Greca.- Biofinformatics engineer

Alejandro La Greca

Bioinformatics Engineer

Razan Hijazi

Research Scientist

Delfina  De Lillo

Jr Accounting Analyst

Florencia De Lillo

Bioinformatics Analyst

Estefania Mancini

Sr Bioinformatics Manager

Alan M. Möbbs

Bioinformatic Analyst

María Olivera - Clinical coordinator

María Olivera

Clinical Ops Manager

Rosana Paggio - Head of clinical operations

Dr. Rosana Poggio

Head of Medical Affairs

Steven Ramondt - Marketing and communications

Steven Ramondt

Creative & Communications

Pat Rickert



Claudia Solari

Sr Research Scientist


Jon Warner - Chair

Los Angeles, CA, USA

Serial entrepreneur, and MBA/PhD with extensive contacts across the US in Healthcare/Healthtech with expertise in Leadership, Management, and Business Development in venture-backed health-technology focused startups/early-stage companies.

Nir Ayalon, Advisor

Nir Ayalon

Tel Aviv, Israel

Serial entrepreneur and
computer scientist with contacts
in Europe and Israel, and expertise
in data science, engineering and
data privacy.

Carl Cook - Advisor

Carl Cook

Cambridge, MA, USA

Senior pharmaceutical executive
based in Boston with 20+ years of
experience in clinical oncology and
precision medicine.

Uday Phadke

Cambridge, UK

A serial entrepreneur and part-time academic based in Cambridge UK. He is the originator of the TripleChasm Approach, which challenges current dogma about how innovations are commercialised.

Paul Sanders

Raleigh, NC, USA

25+ years of experience as a strategist, teacher, and leader focused in product development, sales management, commercialisation and business development

Our partners





Contact us

For more information and presentation of our offering, please contact us.

Thank you for contacting us. We will be respond to your inquiry as soon as possible.
Oops! Something went wrong while submitting the form.